Anemia

A study conducted in seven sub-Saharan African countries demonstrated an association between malaria and an increased prevalence of anemia among pregnant women, according to findings published in BMC Pregnancy and Childbirth.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discusses challenges of anemia management in CKD.

The addition of eltrombopag to standard immunosuppressive therapy appeared safe and increased response rates among transplant-ineligible patients with severe aplastic anemia, according to results of the randomized phase 3 RACE trial.

Analyses of data from two clinical trials and a real-world study revealed an increased risk for anemia among adults with type 2 diabetes prescribed metformin.

In patients with anemia who present with MI, a restrictive blood transfusion strategy was noninferior to liberal transfusion for preventing major adverse CV events at 30 days, according to results of the REALITY trial.

An analysis of published studies showed relief of fatigue for patients with chronic kidney disease and anemia when treatment with erythropoietin stimulating agents led to hemoglobin levels higher than currently recommended targets.

The European Medicines Agency has accepted a marketing authorization application from Astellas Pharmaceuticals for its hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat for the treatment of anemia in adult patients with chronic kidney disease.

For years, the kidney community has debated the merits of “adequate” vs. “optimal” dialysis. Of equal contention has been the decision about when to start dialysis, according to recent interviews and published papers.

Frailty was linked to postprocedural bleeding in older patients undergoing transcatheter aortic valve replacement or surgical AVR, according to a study published in JACC: Cardiovascular Interventions.

Akebia Therapeutic’ s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor showed positive results in the first of two global phase 3 cardiovascular outcomes programs when compared to darbepoetin alfa for the treatment of anemia in patients on dialysis, company officials said.